Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly
variable disease severity and a bimodal course characterized by acute respiratory viral …

In the absence of effective countermeasures, human convalescent plasma has been widely
used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel …

Understanding the trajectory, duration, and determinants of antibody responses after SARS-
CoV-2 infection can inform subsequent protection and risk of reinfection, however large …

Prolonged Covid‐19 is an emerging issue for patients with lymphoma or immune deficiency.
We aimed to examine prolonged length of in‐hospital stay (LOS) due to Covid‐19 among …

Evolution of SARS-CoV-2 in immunocompromised hosts may result in novel variants with
changed properties. While escape from humoral immunity certainly contributes to intra-host …

Outcome of early treatment of COVID‐19 with antivirals or anti‐spike monoclonal antibodies
(MABs) in patients with haematological malignancies (HM) is unknown. A retrospective …

Background Our objective is to describe the presentation and complications, including
relapses, of coronavirus disease 2019 (COVID-19) in patients under anti-CD20 treatments …